NDA vs. BLA vs. ANDA: what peptide drug application numbers mean

01

Application type is the start of the status check

FDA marketing approval is product-specific. The agency evaluates an application containing evidence and information about the drug or biological product, proposed conditions of use, labeling, manufacturing, and quality. The application type reflects the legal pathway and product category; it does not tell a consumer whether the product suits an individual patient.

Peptide markets make the acronyms easy to misuse. A clinic may call an ingredient 'an NDA drug,' a manufacturer may announce that an application was submitted, or a seller may display an application number alongside another formulation. The useful question is narrower: which exact approved product and presentation does this application cover, what is its current status, and does the product being offered match it?

Most FDA-approved human drugs and therapeutic biological products can be researched in Drugs@FDA by brand, active ingredient, or application number. FDA explains that approved human drugs carry NDA or ANDA numbers and approved therapeutic biological products carry BLA numbers. These six-digit numbers help separate regulatory files that share an ingredient or commercial name.

02

What a New Drug Application asks FDA to decide

An NDA is the formal application asking FDA to approve a new drug for marketing in the United States. FDA describes the NDA as the drug's full story, including preclinical and clinical evidence, proposed labeling, safety updates, pharmacology, statistics, manufacturing, and other information needed to evaluate whether the drug is safe and effective for its intended use and can be made with adequate controls.

An NDA number can cover an original approval and later supplements that change labeling, indications, strengths, formulations, manufacturing, or other aspects. When a provider cites the number, open the application record and determine which approval or supplement supports the statement. The original approval date does not automatically date every later presentation or use.

A filed NDA is not an approved NDA. Submission asks for review; filing indicates FDA accepted the application for substantive review; a PDUFA goal date targets an action; and an approval letter authorizes the identified product and conditions. FDA can instead refuse to file, issue a complete response, or take another action. Marketing language should state the actual milestone.

03

What a Biologics License Application covers

A BLA asks FDA to approve marketing of a biological product. FDA's therapeutic-biologics examples include recombinant therapeutic proteins, cytokines, growth factors, enzymes, immunomodulators, monoclonal antibodies, and other listed categories. Whether a peptide-related product follows an NDA or BLA pathway depends on the specific product and regulatory framework, not on a clinic's use of the word peptide.

BLA records should be matched to the proper name, proprietary name, applicant, presentation, labeled indication, and current license. The Purple Book contains licensed biological products and biosimilar or interchangeable relationships. A BLA number does not mean every biologically similar compound, compounded preparation, or off-label use is separately licensed.

Some products moved from approved NDAs to deemed BLAs under the statutory transition that took effect in 2020. That history is another reason to use current FDA databases instead of assuming the pathway from an old article. The application history can explain why a product appears differently across older and newer records without changing the need to match the exact marketed product.

04

How an ANDA supports generic approval

An ANDA is the application pathway for a generic drug product. It is abbreviated because the applicant generally does not repeat the full animal and human evidence used to establish the reference product's safety and effectiveness. Instead, the applicant relies on FDA's prior finding and must demonstrate the proposed generic meets applicable requirements, including sameness in specified characteristics and bioequivalence or another product-appropriate showing.

FDA describes a generic as comparable to the innovator product in dosage form, strength, route, quality, performance characteristics, and intended use, with permitted differences. Complex peptides can require extensive product-specific analysis of identity, impurities, structure, biological activity, immunogenicity risk, and performance. The word abbreviated does not mean FDA skips product-quality review.

An approved ANDA is listed in the Orange Book with its application and product information. A compounded drug is not an ANDA-approved generic merely because it uses a similar active-ingredient name, dosage form, or marketing comparison. Compounded drugs do not undergo FDA premarket approval, and a pharmacy's 503A or 503B status does not convert a preparation into an approved generic.

05

A product-level application verification workflow

Record the name on the container or prescribing information, active ingredient, manufacturer or labeler, strength, dosage form, route, package, and intended use. Search Drugs@FDA by each name and open the application record. Confirm the NDA, BLA, or ANDA number, application holder, approval status, approval date, action letters, labeling, and discontinued status when relevant.

For NDA and ANDA drug products, use the Orange Book to confirm the listed product and, when comparing generics, therapeutic-equivalence information. For BLA products, use the Purple Book to confirm the licensed product and any biosimilar or interchangeable relationship. DailyMed can help locate current submitted labeling, but FDA explains that current submitted labeling can differ from the last FDA-approved labeling in Drugs@FDA.

If the offered product comes from a compounding pharmacy, research the pharmacy and prescription pathway separately and do not attach the approved brand's application number to it. If the candidate is investigational, an IND or NCT number does not substitute for a marketing application approval. Save URLs and the access date because application records and labeling can change.

• →Exact product and labeler
• →Active ingredient, strength, and dosage form
• →Route and approved use
• →Six-digit application number
• →Application holder and approval letter
• →Orange Book or Purple Book match
• →Compounded or investigational distinction

06

Claims and shortcuts to question

Question 'FDA application pending' when the speaker implies approval, 'same as the NDA drug' without product evidence, 'generic' without an approved ANDA or authorized-generic basis, and 'biologic' as though the chemistry term itself proves a BLA. Also question a bare application number that resolves to another manufacturer, strength, route, or indication.

An approved application does not make every use on a provider page FDA-approved. Off-label prescribing of an approved product is distinct from approval of that use, and a compounded version is distinct from the approved product. The provider should name the exact product, regulatory classification, reason for use, pharmacy, and current label rather than borrowing an acronym as a safety badge.

Application research is not a treatment recommendation. Approval establishes that FDA made a product- and indication-specific benefit-risk decision based on the application; it does not guarantee effectiveness or freedom from harm for every person. An appropriately licensed clinician must interpret the current label, evidence, contraindications, alternatives, and patient history.